We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Use of Dried Blood Samples Facilitates Tracking of COVID-19 Antibodies

By LabMedica International staff writers
Posted on 13 Oct 2020
A recent study confirmed that dried blood spot samples could be used as an alternative to venous blood for detecting antibodies to the SARS-CoV-2 virus (COVID-19).

A confirmed diagnosis of COVID-19 depends on the detection of RNA from the coronavirus. More...
In contrast, while serological testing is less useful for diagnosing the acute stages of infection, it is vitall for determining prior virus exposure at a population level.

Currently, antibody testing for COVID-19 uses serum or plasma collected by venipuncture. The use of such sampling in large-scale seroepidemiologic studies is limited by logistic challenges, resources, and costs. In contrast, dried blood spot (DBS) sampling, which is a well-established method for preserving antibodies against various infections, is simple, inexpensive, and can be self-collected and then sent by postal services to laboratories for processing.

Up to now, the potential role of DBS sampling for studying the prevalence of SARS-CoV-2 antibodies has not been fully explored, and knowledge regarding the recovery of such antibodies from the DBS is limited.

To improve this situation, investigators at the University of Birmingham (United Kingdom) described the validation of DBS samples against matched serum in a highly sensitive and specific SARS-CoV-2 ELISA.

The investigators analyzed serum and DBS samples from volunteers at University Hospitals Birmingham Foundation NHS Trust, some of whom had previously tested positive for SARS-CoV-2 by molecular tests, while the status of other volunteers was either negative or unknown. Results revealed that relative to serum samples, DBS samples achieved 98% sensitivity and 100% specificity for detecting anti-SARS-CoV-2 S glycoprotein antibodies. Furthermore, 100% of PCR-positive samples were also antibody-positive in DBS.

Senior author Dr. Matthew O'Shea, a researcher in the institute of immunology and immunotherapy at the University of Birmingham, said, "Our results have demonstrated that dry blood spot sampling not only offers a viable alternative for antibodies testing, but one that overcomes the limitations that current methods can present by eliminating the need for skilled phlebotomists. DBS offers the opportunity for wider population-level testing and improved surveillance in vulnerable groups such as patients with chronic conditions, the immunocompromised, and the elderly by removing the need to come into contact with a healthcare professional during sample collection."

The study was published in the December 2020 online edition of the journal Emerging Infectious Diseases.

Related Links:
University of Birmingham


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.